Introduction
Interplay between the immune system and haemostasis has long been recognized, 1, 2 and in recent years, interactions between the complement and coagulation systems have arisen as a field of considerable interest. 3 The lectin pathway of the complement system is a relatively new player in this field, but increasing amounts of evidence support a crosstalk between lectin pathway proteins and coagulation, at least in vitro. 4 Investigating these interactions more closely may improve our understanding of the pathogenesis of thrombosis in conditions with increased immunologic activation.
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Abstract
The lectin pathway of the complement system can activate the coagulation system in vitro, but the role of the lectin pathway in haemostatic activation and thrombosis in vivo is not clear. We performed a systematic review of the existing literature on associations between the lectin pathway and arterial and venous thrombosis, in accordance with the Assessing the Methodological Quality of Systematic Reviews guidelines. PubMed and Embase were searched from January 1990 to March 2017. We included original studies on human study populations investigating associations between the lectin pathway (protein serum levels, genotype or gene expression) and thrombotic conditions or laboratory coagulation markers. Exclusion criteria were case studies including fewer than five cases, conference abstracts or any other language than English. In total, 43 studies were included which investigated associations between the lectin pathway and cardiovascular thrombotic events (CVEs) (n ¼ 22), ischaemic stroke (n ¼ 9), CVE and stroke (n ¼ 1) and other conditions (systemic lupus erythematosus [n ¼ 6], sepsis-related coagulopathy [n ¼ 3], pulmonary embolism [n ¼ 1], asparaginase treatment [n ¼ 1]). Studies on the lectin pathway and CVE risk reported discrepant results, as both high and low mannose-binding lectin (MBL) serum levels were found to correlate with increased CVE risk. In ischaemic stroke patients, occurrence of stroke as well as increased stroke severity and poor outcome were consistently associated with high serum MBL. For other thromboembolic conditions, only few studies were identified. In conclusion, lectin pathway activation may negatively influence outcome after ischaemic stroke and possibly contribute to CVE risk. Further research is warranted to elucidate the role of the lectin pathway in other thrombotic conditions. interact with C-reactive protein and pentraxin-3, 9-12 contribute to pathogen opsonization 13, 14 and stimulate a proinflammatory cytokine response. 15 Moderate increases in lectin pathway protein serum concentrations have been described during the acute phase response, although these findings contrast to some degree. [16] [17] [18] [19] [20] Associations between Lectin Pathway Protein Levels and Disease
Serum levels of lectin pathway proteins show considerable inter-individual variation, particularly the MBL. 21 The genetic background for this variation, as well as possible associations between low serum levels and increased susceptibility to disease, have been investigated during the years. Some polymorphisms are consistently associated with either higher or lower serum protein levels and with increased disease risk, while such associations are less clear for other polymorphisms. ►Table 1 provides an overview of the most commonly described lectin pathway gene polymorphisms and of some clinical conditions associated with lower or deficient lectin pathway protein levels. Around 10% of the general population have low serum MBL levels. 22 The clinical importance of this is still discussed;
but it is well established that MBL deficiency is a risk factor for infection in susceptible populations. [23] [24] [25] [26] However, the exact role of serum MBL levels in infection and the Lower serum levels: Promoter -550; "H" (wild-type) or "L" (G -> C) allele Promoter -221; "Y" (wild-type) or "X" (G -> C) allele 5′-untranslated region þ4; "P" or "Q" allele (C -> T) Exon 1 (wild-type allele denoted "A"): p.Arg52Cys ("D" allele), p.Gly54Asp ("B" allele), p.Gly57Glu ("C" allele)
Deficiency: Bronchiectasia 129 and increased infection risk in vulnerable populations, e.g. neonates 130 and chemotherapy-treated patients 131, 132 Worse outcome in pneumonia 133 Increased risk of spontaneous recurrent abortion [134] [135] [136] Ficolin-1 FCN1
Higher serum levels: Promoter -542G > A and -144C > A variants 137 Lower serum levels: p.Ala218Thr, p.Asn289Ser, p.Ser268Pro 138 Promoter -542 and -144 variants associated with worse outcome in systemic inflammation and leprosy 137, 139 Ficolin-2 FCN2
Higher levels: Promoter -602G > A, promoter 4A > G 140 Lower levels: Promoter -986A > G, p.Ala258Ser 140 Common variable immunodeficiency 29 
Ficolin-3 FCN3
Deficiency: p.Leu117-frameshift (þ1637DelC) 28 Pneumonia, bronchiectasia, 28, 29 and necrotising enterocolitis 30 
CL-L1 COLEC10
Higher serum levels: p.Arg125Trp 141 Deficiency: p.Arg9Ter, p.Cys176Trp, p.Gly77Glu-frameshift 33 Deficiency: 3MC syndrome 33 
CL-K1 COLEC11
Lower serum levels: p.Arg216His exon 8 variant: G/G and G/A variants associated with lower CL-K1 levels than A/A variant, 142 promoter -9570C > T 
Associations between Lectin Pathway Proteins and Coagulation
Several studies have investigated associations between the lectin pathway and coagulation in vitro. An overview is presented in ►Table 2 and ►Fig. 2. MASP-1 and -2 show affinity for a range of substrates, and MASP-1 shares similarities with prothrombin and MASP-2 with coagulation factor (F)Xa. 58 The ability to cleave prothrombin and generate active thrombin has also been demonstrated for rMASP-2 and MBL-MASP-2 complexes. 59 Notably, for both MASP-1 and MASP-2, cleavage of coagulation proteins and clot formation happened at a lower rate than FXa-and/or thrombin-induced cleavage, 52, 59 and MASP-1-and thrombin-induced clots were also found to differ in density and structure.
53
There is evidence that the coagulation system can activate the lectin pathway in turn. Endo et al demonstrated that murine ficolin and MBLs bind to fibrinogen and fibrin, and that fibrinogen induces lectin pathway activation in mouse serum. 60 Kozarcanin et al showed that ficolins are capable of binding to the surface of activated platelets, and that fibrin binds MASPs and induce MASP-C1-inhibitor or MASP-antithrombin complex formation, indicating MASP activation.
61
Finally, Keizer et al found that tissue factor pathway inhibitor, an endogenous inhibitor of coagulation, can bind and inhibit MASP-2 activation. 62 Thus, crosstalk between the lectin pathway and coagulation occurs at several points, and interactions between lectin pathway proteins and coagulation could contribute to hypercoagulability and increased thrombosis risk in a range of clinical conditions. Our aim was to systematically review the existing literature on associations between the lectin pathway and thrombotic conditions in humans.
PubMed ((((((((((((((((("Complement Pathway 
OR "lectin pathway") OR "lectin pathway activation") OR "mannose-binding lectin") OR "mannan-binding lectin") OR "mannose-binding lectin associated serine protease") OR "mannose-binding lectin associated serine proteases") OR "map19") OR "map44") OR "collectin l1") OR "collectin 10") OR ficolin Ã )) AND (((((((((((((((((((((((("Embolism and Thrombosis 
OR "blood coagulation") OR "platelet activation") OR "arterial thrombosis") OR "venous thrombosis") OR "venous thromboembolism") OR "disseminated intravascular coagulation") OR "myocardial infarction") OR "cardiovascular disease") OR "ischemic stroke") OR "hemorrhagic stroke") OR "renal artery thrombosis") OR The Lectin Pathway in Thrombotic Conditions Larsen et al. 1145
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"mesenteric thrombosis") OR "hepatic thrombosis") OR "peripheral artery occlusion"). 
Inclusion and Exclusion
The inclusion criteria were: (1) original work, (2) human study population and (3) investigating associations between the lectin pathway and thromboembolic disease or laboratory coagulation parameters (surrogate endpoints for increased thrombosis risk). Both interventional and observational studies, including prospective cohort studies as well as case-control studies, were eligible for inclusion. Accepted endpoints for the lectin pathway were plasma or serum protein levels, genetic polymorphisms, gene expression and activation assays for one or more of the following proteins: MBL, ficolin-1, -2, -3, CL-L1 or -K1, MASP-1, -2, -3, MAp44 and MAp19. Accepted endpoints for thromboembolic disease were both microscopic thrombosis (e.g. disseminated intra-vascular coagulation) and large vessel occlusion, and both arterial and venous thrombosis. We included acute ischaemic stroke and cardiovascular thrombotic events (CVEs) defined as acute coronary syndrome (myocardial infarction [MI] and unstable angina pectoris) but not transient cerebral ischaemia, stable angina pectoris or atherosclerotic lesions without sign of thrombosis. Exclusion criteria were (1) case studies including fewer than five cases, (2) other language than English and (3) conference abstracts.
Fifty abstracts were randomly selected and screened for either exclusion or full-text reading by all three authors, and any disagreement was solved by consensus. The remaining abstracts were screened by J.B.L. In a similar fashion, 20 papers proceeding to full-text reading were randomly selected and read in full by all authors, and any disagreement was again solved by consensus. Inclusion or exclusion of the remaining papers were performed by J.B.L., and in case of doubt, all three authors discussed the study in question. systematically assessing the risk of different types of bias in the study and thus the internal validity of the results. The tools comprise a list of items concerning key methodological points and specific criteria to be fulfilled for each item. A numeric rating scale is not employed; instead, each study is rated 'good', 'fair' or 'poor' according to the estimated risk of serious bias (low, intermediate or high), which is based on the number and types of criteria not fulfilled. Quality assessment was performed by all the three authors for all included studies, and disagreement was solved by consensus.
Data Extraction and Quality Assessment

Data Synthesis
The included studies were heterogeneous regarding the design, study populations and endpoints, thus a complete meta-analysis of the data was not performed. Forest plots were made for the CVE sub-group to visualize results and support our qualitative data synthesis using Stata 14 (StataCorp, Texas, United States). If data for forest plots could not be extracted from the included article, an attempt to obtain data was made via emails to the corresponding authors.
Results
In total, 43 original articles were included in the present review and are presented in ►Tables 3-6. The screening and inclusion/exclusion process is displayed in detail in ►Fig. 3.
We grouped the studies first according to their major clinical focus and second according to their design. Among The Lectin Pathway in Thrombotic Conditions Larsen et al. 1147
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. Additionally, some included one or more of three polymorphisms in the promoter or 5′ untranslated region 37, 68, 72, 74, 75, 77, 80, 94, 97, 99 (please refer to ►Table 1). All studies classified the patients' genotypes or haplotypes after their known association with MBL expression and serum levels. Thus, genotype was classified overall as 'high' (wild-type), 'intermediate' or 'low' in these studies, and this classification is used throughout the text and tables of the present review.
The overall study quality was moderate to high, with 22 (51%) rating 'good', 17 (40%) rating 'fair' and 4 (9%) rating 'poor'. The individual ratings are provided in ►Tables 3-6.
Below, we summarize the findings of the included studies on associations between the lectin pathway and thrombotic events. The Lectin Pathway in Thrombotic Conditions Larsen et al. 1151
Cardiovascular Events
The Lectin Pathway and Occurrence of Cardiovascular Events The Lectin Pathway in Thrombotic Conditions Larsen et al. 1153
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. The Lectin Pathway in Thrombotic Conditions Larsen et al. 1155 Abbreviations: aPTT, activated partial thromboplastin time; CABG, coronary artery bypass grafting; CL-K1, collectin kidney 1; DIC, disseminated intravascular coagulation; DVT, deep vein thrombosis; EDTA, ethylenediaminetetraacetic acid; ELISA, enzyme-linked immunosorbent assay; EIA, enzyme immunoassay; F, coagulation factor; HR, hazard ratio; ISTH, International Society on Thrombosis and Haemostasis; LP, lectin pathway; MASP, MBL-associated serine protease; MBL, mannose-binding lectin; MBL2, gene encoding MBL; MI, myocardial infarction; mRNA, messenger ribonucleic acid; OR, odds ratio; PE, pulmonary embolism; PT, prothrombin time; SLE, systemic lupus erythematosus; ROC, receiver operator characteristics; TAT, thrombin-anti-thrombin. Note: Study population: Age, gender and ethnicity are stated if reported in the study. Age is rounded to whole years and indicated by mean AE standard deviation or median (interquartiles) unless otherwise specified. Results: Numbers in parentheses after OR/HR/area under ROC curve are 95% confidence intervals unless otherwise specified. Four studies analysed MAp44, of which three found no association between this protein and CVE, 45, 73, 95 while one study reported increased MAp44 levels in MI patients versus healthy controls.
84
The Lectin Pathway and Outcome in Existing Cardiovascular Disease
The nine studies investigating the association between lectin pathway proteins and outcome in patients with pre-existing CVE are presented in ►Table 4. All studies included study populations with recent MI; most having undergone either CABG or PCI in the early phase of the study. The following 84 Schoos et al demonstrated no association between MAp44 alone and cardiac function either, but reported that both high ficolin-2 alone and a combination of high ficolin and low MAp44 were associated with impaired cardiac function (higher end-systolic and end-diastolic volumes).
83
Ischaemic Stroke
The Lectin Pathway and Occurrence of Ischaemic Stroke Eight case-control studies investigated lectin pathway patients with ischaemic stroke versus healthy controls. [86] [87] [88] [89] [90] [91] [92] 95 In general, stroke was diagnosed according to valid diagnostic criteria and/or verified with radiological imaging. Among the five studies analysing MBL, four studies reported higher serum MBL levels in stroke patients compared with healthy controls. 87, [89] [90] [91] High MBL was moderately associated with the occurrence of stroke with areas under the receiver operator characteristics (ROC) curves ¼ 0.76. 87, 91 In contrast, one study found no association between plasma MBL and ischaemic stroke. The Lectin Pathway in Thrombotic Conditions Larsen et al. 1159
Zangari et al found lower levels of ficolin-1, -2 and -3 during the early phase of stroke and a strong association between low ficolin-1 at 6 hours and stroke occurrence (area under the ROC curve ¼ 0.91). 88 This was in accordance with
Füst et al who also reported low ficolin-2 and -3 levels at admission in stroke patients. 92 Index. 93 The only study investigating MBL2 genotype supported these findings, reporting that both high serum MBL and high genotype was associated with an unfavourable outcome. 94 Song et al calculated the ability of MBL to predict mortality and functional outcome, finding moderate areas under the ROC curves (0.85 for mortality and 0.75 for Rankin Scale). 89 Only one study did not find an association between MBL and stroke severity or functional outcome.
88
With regards to other lectin pathway proteins, Kouchaki et al found a significant positive correlation between ficolin-1 and NIHSS score, 86 indicating that high ficolin-1 levels are associated with more severe stroke. This contrasted with Zangari et al who found no association between ficolins and NIHSS score, but reported an association between low ficolin-1 and unfavourable outcome on modified Rankin Scale. 88 Füst et al found that low ficolin-3 at day 3 after stroke was associated with unfavourable outcome, but also with less initial stroke severity.
92
Other Conditions
Systemic Lupus Erythematosus
Four studies examined associations between MBL2 genotypes and thrombotic events in SLE patients.
96-99
Øhlenschlaeger et al reported that low genotype was associated with increased risk of arterial thrombosis, defined as cardiovascular, cerebrovascular or peripheral vascular events, but not with venous thrombosis. 99 The three remaining studies found no independent association 96, 97 or only a borderline significant association 98 between MBL2 genotype and thrombotic events. Hein et al reported that SLE patients with a history of arterial but not venous thrombosis had significantly higher circulating ficolin-1 levels. 41 The method for verifying a previous thrombotic event was not reported, nor could it be found in the original source cited. Kozarcanin et al did not include clinical endpoints, but investigated correlations between MASP-1 and -2 activation and platelet and coagulation parameters in SLE patients and multi-trauma patients.
61
The authors reported that MASP activation correlated significantly with activation of both primary and secondary haemostasis in both patient groups.
Disseminated Intravascular Coagulation
Sprong et al investigated the association between MBL2 genotype and coagulation parameters and clinical manifestations indicating DIC in children with meningococcal disease and septic shock. 103 Children with low genotype (n ¼ 2 of 18) had a lower DIC score, and their platelet counts and fibrinogen levels were markedly closer to the normal range compared with children with intermediate or high genotype. Due to the small number of patients, statistical significance was not calculated. In a study on adult sepsis patients, Zhao et al reported higher MBL levels in patients with overt DIC at admission and in patients who developed DIC later compared with patients without DIC, but MBL was not found to be an independent predictor for the development of DIC. 104 In both the DIC and non-DIC group, the mean MBL serum level was well below the range reported by other authors in healthy individuals, 21 and the difference between the DIC and non-DIC group, although statistically significant, was subtle. Finally, Takahashi et al investigated CL-K1 in 549 patients with DIC of various aetiologies and found that DIC was associated with higher CL-K1 levels.
102
Other Studies
Lv et al conducted a case-control study in patients with pulmonary embolism and healthy controls and extensively investigated complement-related messenger ribonucleic acid (mRNA) expression. 100 They found lower expression of MBL2 and MASP2 mRNA in patients with pulmonary embolism compared with healthy controls. Finally, Merlen et al investigated serum-MBL, fibrinogen, anti-thrombin and thrombotic events in paediatric patients who were treated with L-asparaginase, 101 a chemotherapeutic drug with a known pro-thrombotic effect. The main finding related to the scope of the present review was that MBL correlated positively, although only weakly, with both fibrinogen and anti-thrombin.
Discussion
The present systematic review did not reveal a consistent association between the lectin pathway and thrombotic conditions. MBL serum levels and/or genotype were the most commonly investigated lectin pathway parameters.
An association between MBL and CVE occurrence or outcome was observed in several studies but differed in both effect size and direction. In ischaemic stroke patients, high serum MBL was consistently associated with occurrence of stroke as well as increased stroke severity and unfavourable outcome. Only few studies on other thrombotic conditions were identified. In general, the included studies were of high quality, with 90% rating 'good' or 'fair' using the National Institute of Health quality assessment tools. This indicates a low risk of bias and overall high validity of the results. Among the 43 studies, 29 (67%) were prospectively designed, while the rest was cross-sectional or case-control studies. CVE (n ¼ 23), ischaemic stroke (n ¼ 10), SLE-associated thrombosis (n ¼ 6) and sepsis-associated DIC (n ¼ 3) were the most commonly investigated thrombotic conditions. Almost all studies had clinical thromboembolic disease as their main outcome, and only five studies used laboratory coagulation parameters as endpoints.
61,101-104 A variety of materials (serum, ethylenediaminetetraacetic acid plasma, citrated plasma) were used for lectin pathway protein analysis, as well as different assays (enzyme-linked immunosorbent assay, time-resolved immunofluorometric assay); however, there did not seem to be an association between the materials or assays used and the reported results. As summarized in the introduction, the available in vitro evidence consistently reports that MBL and MASP-1 and -2 can activate the coagulation system. This is supported by animal studies. Studies on induced carotid artery and cerebral thrombosis in murine models found that MBL-deficient mice had preserved carotid blood flow 105, 106 and less intravascular fibrin deposition 107 compared with wild-type mice.
Takahashi et al demonstrated a prolonged tail bleeding time in MBL-deficient mice which could be restored with recombinant MBL. Taken together, the available evidence from in vitro and animal studies thus suggests a pro-coagulant effect of lectin pathway activation and a protective role of MBL deficiency on thrombus development. The results of the present systematic review do not unequivocally support these findings of in vitro and animal studies. The included studies reported conflicting results, especially regarding the role of the lectin pathway in cardiovascular thrombosis. Both high 37, 69 and low 66,67 MBL levels were reported to be risk factors for CVE, while two large cohort studies found no overall influence of serum MBL on future CVE risk. 70, 71 A probable explanation of these conflicting results could be the diversity in study populations; they all carried an increased CVE risk but differed with regards to the underlying pathophysiology and baseline risk of thrombotic events. Furthermore, follow-up times varied, and a variety of endpoints or combinations of endpoints were employed. The studies on ischaemic stroke more consistently reported associations between high MBL levels and stroke occurrence as well as severity 87, [89] [90] [91] 93 with a single exception. 88 The ficolins were investigated in three studies only. 86, 88, 92 Associations between both ficolin-1 and ficolin-3 and stroke severity and long-term outcome were described; however, the findings were contrasting, and the scarcity of studies make it difficult to conclude on the role of ficolins in ischaemic stroke. An association between high MBL and unfavourable outcome was also consistently reported after stroke, In SLE patients, one well-conducted follow-up study demonstrated that low MBL genotype was associated with higher risk of arterial thrombotic events, 99 but three other studies on SLE patients could not reproduce these findings. [96] [97] [98] Two studies investigated associations between MBL and sepsis-related DIC 103,104 and both reported higher MBL levels to be associated with more severe coagulation disturbances. However, one study was very small (n ¼ 18), 103 while in the second study, only a discrete difference in MBL levels was observed between the DIC and non-DIC group, and MBL was not found to be an independent predictor of DIC in sepsis. 104 Thus, the influence of the lectin pathway on coagulation and thrombosis risk in both SLE and sepsis remains uncertain. We included both arterial and venous thrombosis in the present review, with the majority of included studies focusing on arterial thrombotic events. Although arterial and venous thrombosis include several common factors, the mechanisms behind them differ considerably. Coronary and cerebral artery thrombosis usually includes a component of atherosclerosis. This is a complex condition characterized by chronic low-grade inflammation with activation of several immune system components, 118,119 which may have been on-going for a long period of time before the major thrombotic event takes place. Activated platelets are also a key component of atherosclerosis, as they are activated by oxidized LDL and activated endothelial cells in the atherosclerotic plaque. In turn, they activate and uphold inflammation by facilitating monocyte migration, activating neutrophils and secreting pro-inflammatory factors.
120,121
Interestingly, cholesterol crystals in the atherosclerotic plaque may play a role in activating the lectin pathway directly, 122 and in diabetic patients, altered endothelial The Lectin Pathway in Thrombotic Conditions Larsen et al. 1161
glycosylation patterns may further cause MBL binding and lectin pathway activation. 42 Venous thrombosis, on the other hand, is driven largely (though not exclusively) by activation of secondary haemostasis, and traditional risk factors are hypercoagulability, loss of endothelial integrity with tissue factor exposure and decreased blood flow or stasis.
123
Hypercoagulability can be inherited, but one of the major risk factors for venous thrombosis is inflammation, potentially induced by bacterial infection, autoimmune disease and traumatic or surgical acute phase response. The inflammationinduced hypercoagulability is driven by pro-inflammatory cytokines such as interleukin-6 and caused by an increased production of pro-coagulant factors such as tissue factor, fibrinogen, FVIII, von Willebrand factor and plasminogen activator inhibitor-1, as well as decreased production of the endogenous anti-coagulants, anti-thrombin protein C and S. 123, 124 The venous thrombosis is often an acute event in
itself, but local inflammatory changes in the vessel can persist and lead to chronic venous disease.
125,126
The lectin pathway is an interesting potential contributor to inflammation-driven hypercoagulability and thrombosis through direct activation by MASPs, as described in the introduction. Since there is considerable crosstalk and mutual activation between the coagulation system and the lectin pathway, they may well activate each other in thrombotic and inflammatory conditions and thereby uphold the inflammatory and hyper-coagulable response in a vicious cycle. This emerging concept of immunothrombosis-or thromboinflammation-has recently been discussed. 123, 127 However, it should be noted that since changes in both lectin pathway proteins and coagulation factors occur during the acute phase response, any observed correlation between plasma levels does not equal causation, but may simply indicate that an acute phase reaction is on-going. It should also be considered that although there is solid evidence that MASPs are able to induce clot formation in vitro, this occurs at a lower rate than thrombin-induced clot formation. 52 Furthermore, MASP-1-induced fibrin clots were found to be less dense and with thicker fibres than thrombininduced clots. 53 This type of clots has been found more susceptible to lysis. 128 Thus, the lectin pathway may have not a merely pro-coagulant but also a modulatory effect on coagulation, which could be clinically important. The strengths of the present review were that we assessed the literature systematically, searching both PubMed and Embase and using broad search terms to minimize the risk of overlooking relevant studies. We performed a formal quality assessment and found the vast majority of studies to be of good or fair quality, which strengthens the validity of their results and our conclusions. The majority of studies included clinical endpoints for thromboembolic disease. However, some limitations should be mentioned. The study populations and endpoints for thrombosis were heterogeneous, and only few studies on thromboembolic conditions other than CVE and stroke were identified. This limits the value of comparison across all the identified studies and makes it impossible to conclude on the significance of the lectin pathway in the development of thrombotic conditions in a broader clinical setting.
To conclude, the existing evidence indicates that lectin pathway activation is associated with poor outcome after ischaemic stroke. Furthermore, there is some evidence for involvement of the lectin pathway in CVEs, although the exact role of the lectin pathway in this setting is not yet fully elucidated. With regards to other thrombotic conditions, only sparse clinical evidence exists, and future studies in this field are warranted. 
